Chemical Reviews pubs.acs.
org/CR Review
(115) Dixit, A.; Verkhivker, G. M. The Energy Landscape Analysis of (130) Zou, H. Y.; Friboulet, L.; Kodack, D. P.; Engstrom, L. D.; Li,
Cancer Mutations in Protein Kinases. PLoS One 2011, 6, e26071. Q.; West, M.; Tang, R. W.; Wang, H.; Tsaparikos, K.; Wang, J.; et al.
(116) Soda, M.; Choi, Y. L.; Enomoto, M.; Takada, S.; Yamashita, PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to
Y.; Ishikawa, S.; Fujiwara, S.; Watanabe, H.; Kurashina, K.; Hatanaka, First and Second Generation ALK Inhibitors in Preclinical Models.
H.; et al. Identification of the Transforming EML4-ALK Fusion Gene Cancer Cell 2015, 28, 70−81.
in Non-Small-Cell Lung Cancer. Nature 2007, 448, 561−566. (131) Drilon, A.; Ou, S. I.; Cho, B. C.; Kim, D. W.; Lee, J.; Lin, J. J.;
(117) De Carlo, E.; Del Savio, M. C.; Polesel, J.; Da Ros, V.; Berto, Zhu, V. W.; Ahn, M. J.; Camidge, D. R.; Nguyen, J.; et al.
E.; Santarossa, S.; Chimienti, E.; Fratino, L.; Bearz, A. Outcomes of Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK
ALK Positive Lung Cancer Patients Treated with Crizotinib or Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front
Second-Generation ALK Inhibitor: A Monoinstitutional Experience. Mutations. Cancer Discovery 2018, 8, 1227−1236.
Oncotarget 2018, 9, 15340−15349. (132) Fujita, K.; Nonomura, N. Role of Androgen Receptor in
(118) Jia, Y.; Yun, C. H.; Park, E.; Ercan, D.; Manuia, M.; Juarez, J.; Prostate Cancer: A Review. World J. Mens Health 2019, 37, 288−295.
Xu, C.; Rhee, K.; Chen, T.; Zhang, H.; et al. Overcoming (133) Perlmutter, M. A.; Lepor, H. Androgen Deprivation Therapy
EGFR(T790M) and EGFR(C797S) Resistance with Mutant-Selective in the Treatment of Advanced Prostate Cancer. Rev. Urol. 2007, 9,
Allosteric Inhibitors. Nature 2016, 534, 129−132. S3−S8.
(119) Marsilje, T. H.; Pei, W.; Chen, B.; Lu, W.; Uno, T.; Jin, Y.; (134) Prekovic, S.; van Royen, M. E.; Voet, A. R.; Geverts, B.;
Jiang, T.; Kim, S.; Li, N.; Warmuth, M.; et al. Synthesis, Structure-
Houtman, R.; Melchers, D.; Zhang, K. Y.; Van den Broeck, T.;
Activity Relationships, and In Vivo Efficacy of the Novel Potent and
Smeets, E.; Spans, L.; et al. The Effect of F877L and T878A
Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-chloro-N2-
Mutations on Androgen Receptor Response to Enzalutamide. Mol.
(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropyl-
sulf onyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Cancer Ther. 2016, 15, 1702−1712.
Phase 1 and Phase 2 Clinical Trials. J. Med. Chem. 2013, 56, 5675− (135) Arvinas Announces the Initiation of Patient Dosing in a First-in-
5690. Human Phase 1 Study of ARV-471, an Estrogen Receptor-Targeting
(120) Friboulet, L.; Li, N.; Katayama, R.; Lee, C. C.; Gainor, J. F.; PROTAC® Protein Degrader. Arvinas. August 27, 2019. https://ir.
Crystal, A. S.; Michellys, P. Y.; Awad, M. M.; Yanagitani, N.; Kim, S.; arvinas.com/news-releases/news-release-details/arvinas-announces-
et al. The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance initiation-patient-dosing-first-human-phase-1 (accessed 2020-03).
in Non-Small Cell Lung Cancer. Cancer Discovery 2014, 4, 662−673. (136) Hsu, C. L.; Liu, J. S.; Wu, P. L.; Guan, H. H.; Chen, Y. L.; Lin,
(121) Kinoshita, K.; Ono, Y.; Emura, T.; Asoh, K.; Furuichi, N.; Ito, A. C.; Ting, H. J.; Pang, S. T.; Yeh, S. D.; Ma, W. L.; et al.
T.; Kawada, H.; Tanaka, S.; Morikami, K.; Tsukaguchi, T.; et al. Identification of a New Androgen Receptor (AR) Co-Regulator
Discovery of Novel Tetracyclic Compounds as Anaplastic Lymphoma BUD31 and Related Peptides to Suppress Wild-Type and Mutated
Kinase Inhibitors. Bioorg. Med. Chem. Lett. 2011, 21, 3788−3793. AR-Mediated Prostate Cancer Growth Via Peptide Screening and X-
(122) Kinoshita, K.; Asoh, K.; Furuichi, N.; Ito, T.; Kawada, H.; ray Structure Analysis. Mol. Oncol. 2014, 8, 1575−1587.
Hara, S.; Ohwada, J.; Miyagi, T.; Kobayashi, T.; Takanashi, K.; et al. (137) Altundag, K.; Ibrahim, N. K. Aromatase Inhibitors in Breast
Design and Synthesis of a Highly Selective, Orally Active and Potent Cancer: An Overview. Oncologist 2006, 11, 553−562.
Anaplastic Lymphoma Kinase Inhibitor (CH5424802). Bioorg. Med. (138) Chumsri, S.; Howes, T.; Bao, T.; Sabnis, G.; Brodie, A.
Chem. 2012, 20, 1271−1280. Aromatase, Aromatase Inhibitors, and Breast Cancer. J. Steroid
(123) Vavala, T.; Novello, S. Alectinib in the Treatment of ALK- Biochem. Mol. Biol. 2011, 125, 13−22.
Positive Non-Small Cell Lung Cancer: An Update on its Properties, (139) Portman, N.; Alexandrou, S.; Carson, E.; Wang, S.; Lim, E.;
Efficacy, Safety and Place in Therapy. Ther. Adv. Med. Oncol. 2018, Caldon, C. E. Overcoming CDK4/6 Inhibitor Resistance in ER
DOI: 10.1177/1758835918789364. Positive Breast Cancer. Endocr.-Relat. Cancer 2019, 26, R15−R30.
(124) Lockney, N. A.; Wu, A. J. Alectinib for the Management of (140) Leverson, J. D.; Cojocari, D. Hematologic Tumor Cell
ALK-Positive Non-Small Cell Lung Cancer Brain Metastases. J. Resistance to the BCL-2 Inhibitor Venetoclax: A Product of Its
Thorac. Dis. 2017, 9, E152. Microenvironment? Front. Oncol. 2018, 8, 458.
(125) Petrelli, F.; Lazzari, C.; Ardito, R.; Borgonovo, K.; Bulotta, A.; (141) Petros, A. M.; Huth, J. R.; Oost, T.; Park, C. M.; Ding, H.;
Conti, B.; Cabiddu, M.; Capitanio, J. F.; Brighenti, M.; Ghilardi, M.; Wang, X.; Zhang, H.; Nimmer, P.; Mendoza, R.; Sun, C.; et al.
et al. Efficacy of ALK Inhibitors on NSCLC Brain Metastases: A Discovery of a Potent and Selective Bcl-2 Inhibitor Using SAR by
Systematic Review and Pooled Analysis of 21 Studies. PLoS One NMR. Bioorg. Med. Chem. Lett. 2010, 20, 6587−6591.
2018, 13, e0201425. (142) Park, C. M.; Bruncko, M.; Adickes, J.; Bauch, J.; Ding, H.;
(126) Horn, L.; Infante, J. R.; Reckamp, K. L.; Blumenschein, G. R.; Kunzer, A.; Marsh, K. C.; Nimmer, P.; Shoemaker, A. R.; Song, X.;
Leal, T. A.; Waqar, S. N.; Gitlitz, B. J.; Sanborn, R. E.; Whisenant, J. et al. Discovery of an Orally Bioavailable Small Molecule Inhibitor of
G.; Du, L.; et al. Ensartinib (X-396) in ALK-Positive Non-Small Cell
Prosurvival B-Cell Lymphoma 2 Proteins. J. Med. Chem. 2008, 51,
Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter
6902−6915.
Study. Clin. Cancer Res. 2018, 24, 2771−2779.
(143) Souers, A. J.; Leverson, J. D.; Boghaert, E. R.; Ackler, S. L.;
(127) Das, M. Brigatinib Effective in ALK-Positive Non-Small-Cell
Catron, N. D.; Chen, J.; Dayton, B. D.; Ding, H.; Enschede, S. H.;
Lung Cancer. Lancet Oncol. 2017, 18, e310.
(128) Sabari, J. K.; Santini, F. C.; Schram, A. M.; Bergagnini, I.; Fairbrother, W. J.; et al. ABT-199, a Potent and Selective BCL-2
Chen, R.; Mrad, C.; Lai, W. V.; Arbour, K. C.; Drilon, A. The Activity, Inhibitor, Achieves Antitumor Activity while Sparing Platelets. Nat.
Safety, and Evolving Role of Brigatinib in Patients with ALK- Med. 2013, 19, 202−208.
Rearranged Non-Small Cell Lung Cancers. OncoTargets Ther. 2017, (144) Blombery, P.; Anderson, M. A.; Gong, J. N.; Thijssen, R.;
10, 1983−1992. Birkinshaw, R. W.; Thompson, E. R.; Teh, C. E.; Nguyen, T.; Xu, Z.;
(129) Johnson, T. W.; Richardson, P. F.; Bailey, S.; Brooun, A.; Flensburg, C.; et al. Acquisition of the Recurrent Gly101Val Mutation
Burke, B. J.; Collins, M. R.; Cui, J. J.; Deal, J. G.; Deng, Y. L.; Dinh, in BCL2 Confers Resistance to Venetoclax in Patients with
D.; et al. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15- Progressive Chronic Lymphocytic Leukemia. Cancer Discovery 2019,
oxo-10,15,16,17-tetrahydro-2H-8,4-(m etheno)pyrazolo[4,3-h]- 9, 342−353.
[2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), (145) Birkinshaw, R. W.; Gong, J. N.; Luo, C. S.; Lio, D.; White, C.
a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and A.; Anderson, M. A.; Blombery, P.; Lessene, G.; Majewski, I. J.;
C-Ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Thijssen, R.; et al. Structures of BCL-2 in Complex with Venetoclax
Broad-Spectrum Potency Against ALK-Resistant Mutations. J. Med. Reveal the Molecular Basis of Resistance Mutations. Nat. Commun.
Chem. 2014, 57, 4720−4744. 2019, 10, 2385.
AU https://dx.doi.org/10.1021/acs.chemrev.0c00383
Chem. Rev. XXXX, XXX, XXX−XXX
